Brexit

UK vector
#Brexit #Clinical trials #Drug discovery #Ireland #UK

Biogen’s vision for UK & Ireland  

DDW Editor Reece Armstrong speaks to Kylie Bromley, General Manager and Managing Director of Biogen UK & Ireland, about her career within the life sciences industry and the challenges of navigating a large pharma company within the UK and Ireland.   RA: Could you tell us about your career… Read More

#Exclusive Content

EU flag
#Brexit #Europe #Funding #Horizon Europe #Life sciences #UK government

Horizon Europe delay damaging UK’s reputation as a science leader

As negotiations continue between the UK and EU over Horizon Europe, the largest collaborative research programme in the world, the scientific research community has urged the Prime Minister to secure the UK’s membership as soon as possible.  Figures reported in The Guardian from the European… Read More

#News #Trending News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Two part commentary on Brexit and drug discovery

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#News

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK budget

Part 1: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#Exclusive Content #Regulatory

#Brexit #European Commission #European Medicines Agency #MHRA #Regulatory #UK #UK bidget

Part 2: What impact has Brexit had on UK drug discovery?

On 31 January 2020, the United Kingdom (UK) withdrew from the European Union (EU). Alongside a number of repercussions, the most impactful to the drug discovery sector arguably relates to regulatory affairs on account of adjusting from the European Medicines Agency (EMA) to the Medicines and Healthcare products Regulatory… Read More

#Exclusive Content #Regulatory